Esperion Therapeutics has two approved LDL-C lowering therapies, Nexletol and Nexlizet, but lacks a strong pipeline for future growth.

The paper is published in the journal Cell Reports. The researchers found that ATP-citrate lyase (ACLY), an enzyme involved in converting citrate to acetyl-CoA, plays a critical role in activating ...

which appears to influence substrate preference and the efficiency of the lyase reaction. Mutations at this site can alter the enzyme's active site structure, affecting its catalytic activity[3].

The bacterial mercury-processing enzymes, organomercurial lyase (MerB) and mercuric reductase (MerA), catalyze the following reactions: Mer enzyme concentrations, corrected for total cellular ...